Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.58 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215479 | 1.00 | SIGMAR1 (0.58) | SIGMAR1ACKR3CCR3L3MBTL1POLB | |
| SCHEMBL3670119 | 0.85 | SIGMAR1 (0.58) | SIGMAR1ACKR3CCR3L3MBTL1POLB | |
| SCHEMBL3638457 | 0.84 | OGA (0.59) | SIGMAR1L3MBTL1EPHX2LMNA | |
| SCHEMBL13929427 | 0.83 | SIGMAR1 (0.59) | SIGMAR1CCR3CCR5 | |
| SCHEMBL3810814 | 0.83 | SIGMAR1 (0.56) | SIGMAR1ACKR3CCR3L3MBTL1POLB | |
| SCHEMBL3810819 | 0.83 | SIGMAR1 (0.56) | SIGMAR1ACKR3CCR3L3MBTL1POLB | |
| SCHEMBL5357866 | 0.79 | LMNA (0.69) | SIGMAR1POLBEPHX2LMNA | |
| SCHEMBL13951400 | 0.78 | SIGMAR1 (0.69) | SIGMAR1CCR3L3MBTL1CCR5 | |
| SCHEMBL4220531 | 0.77 | SIGMAR1 (0.54) | SIGMAR1CCR3 | |
| SCHEMBL6988819 | 0.75 | SIGMAR1 (0.66) | SIGMAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | SIGMAR1 129/4885ACKR3 1/4885CCR3 15/4885 |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | SIGMAR1 447/4885ACKR3 509/4885CCR3 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.